Hygea Medical Technology Co., Ltd.

12/01/2026

Hygea Co-Ablation System for Lung Tumors: Clinical Evidence from a Large Retrospective Study

⚕️ New clinical data published in European Journal of Radiology demonstrate that the Hygea Co-Ablation System is a safe and feasible option for the treatment of malignant lung tumors. In more than 200 treatment sessions, co-ablation achieved:

🔹 Acceptable adverse event rates, with pneumothorax comparable to conventional cryoablation
🔹 Significantly lower rates of pleural effusion and hemoptysis
🔹 Favorable local tumor control, particularly in tumors ≤3 cm
🔹 Prolonged progression-free survival in small lesions

By integrating the advantages of cryoablation and high-intensity thermal ablation, the Hygea Co-Ablation System enables precise tumor destruction while maintaining a strong safety profile, supporting its role as a promising minimally invasive solution for lung cancer patients.
Source: Zhang et al., European Journal of Radiology, 2026
Hygea website: https://www.hygeamedtech.com/

12/01/2026

🎉 The first randomized phase II trial evaluating ablation plus immunotherapy in advanced NSCLC with oligo-residual disease

🧠 The BOOSTER study offers the first prospective evidence that adding local ablation to ongoing anti–PD-1/L1 therapy can improve disease control in advanced NSCLC patients with oligo-residual disease. It also helps define a clearer treatment approach for patients who have limited residual lesions after an initial immunotherapy response—an area previously lacking clinical guidance. Read the article: https://www.nature.com/articles/s41392-025-02460-z

💡 Key findings:
· Median progression-free survival more than doubled in the ablation + immunotherapy arm (26.7 months vs. 11.7 months).
· Cryoablation also led to an increase in systemic IFN-α, suggesting a distinct immunologic effect compared with thermal ablation.
· The combination approach demonstrated an overall favorable safety profile.

🔬 Clinical relevance:
Hygea's Co-ablation system may provide more than local tumor control—its immunomodulatory characteristics could offer meaningful support to ongoing immunotherapy, especially for patients with limited residual disease.

This study reinforces the emerging role of ablation as a valuable component within combined minimally invasive and immunotherapeutic strategies.

Local consolidative therapy (LCT) has been demonstrated to enhance the survival benefits of immunotherapy in non-small cell lung cancer (NSCLC) patients with oligometastatic or oligoprogressive disease. This randomized, phase 2 trial investigated the efficacy and safety of ablation combining continu...

10/11/2025

🔬 Fudan Zhongshan Hospital has published a groundbreaking Nature Cancer study demonstrating that combining cryoablation using Hygea's Co-Ablation system with immunotherapy achieves remarkable clinical outcomes in patients with advanced intrahepatic cholangiocarcinoma.
In the CASTLE-01 phase II trial, conducted with Hygea's Co-Ablation system, the treatment achieved an objective response rate of 75%, a disease control rate of 100%, and a median overall survival of 25.4 months.
Read the paper: https://www.nature.com/articles/s43018-025-01058-2

This landmark study underscores how cryoablation can enhance tumor immunogenicity and amplify systemic antitumor immunity — marking a new milestone in immuno-cryoablation cancer therapy.

Wang and colleagues report the clinical results and immunological correlates of a phase 2 clinical trial of cryoablation plus lenvatinib and sintilimab in persons with advanced or metastatic intrahepatic cholangiocarcinoma.

10/11/2025

🚀 Thrilled to unveil the Epic™ Co-ablation System at .!

🎉 We're humbled by the overwhelming response to our breakthrough AI Epic™ Co-Ablation System and a big thank to everyone who took the time to join us at Booth.

Highlights that energized us:
💉 Liquid nitrogen based technology: Faster and larger iceball formation enables larger single-probe abltion zone in its class
🔥 -196°C to +85°C – A nearly 300°C temperature range for precise and safe tumor ablation ❄️

🙌 Special thanks to:
✅ The visionary physicians and partners who engaged in deep-dive discussions about Co-ablation protocols
✅ The tireless organizers for creating this world-class knowledge exchange platform

See you at CIRSE2026!

10/11/2025

🇨🇳🤝🇵🇰 Strengthening Bilateral Ties | B2B Conference – Beijing, China

🎉 Honored to have signed a Memorandum of Understanding (MoU) with ShahCo Medical in the presence of His Excellency the Prime Minister of Pakistan at the 2nd Pakistan-China B2B Investment Conference!

This pivotal agreement, witnessed at the highest level, underscores a shared commitment to advancing cancer care in Pakistan through:
🔬 Establishment of a Co-ablation Training Center
💉 Knowledge transfer & medical training programs
🌍 Joint awareness initiatives

We are grateful for the strong support from the leadership of both nations and are excited to embark on this journey to make a meaningful impact on healthcare outcomes in Pakistan.

See on-site news coverage: https://lnkd.in/gAgtqkqR

10/11/2025

🚀 Groundbreaking Medical Achievement at Mayo Hospital Lahore, Pakistan！

We are thrilled to announce the successful installation and first clinical use of the Co-Ablation system at Mayo Hospital, Pakistan on August 26. 📅

❄️ 🔥 This groundbreaking technology was deployed in its first surgery for liver cancer, targeting a tumor approximately 4.5 cm in size. The procedure was performed seamlessly, and the patient is currently in stable condition with positive postoperative outcomes.

This milestone represents a significant advancement in minimally invasive oncology therapies in Pakistan, underscoring a commitment to integrating cutting-edge technology for improved patient care.
Hope this technology will pave the way for more successful procedures in the future, providing enhanced treatment options and improved outcomes for more cancer patients.

🎉 Congratulations to the entire medical team at Mayo Hospital for their expertise and dedication!

03/07/2025

🌏 Breaking China-Caribbean MedTech Dialogue Concludes in Beijing
Pioneering minimally invasive oncology solutions for global health equity

BEIJING, July 1, 2025 — Hygea Medical was honored to welcome ambassadors & senior diplomats from 10 Caribbean nations for the groundbreaking China-Caribbean Minimally Invasive Oncology Seminar.

💡 Key Highlights:
✅ Tech Showcase: Tour of Hygea's innovation center and demonstrating Hygea's advanced Co-Ablation System alongside all pipeline innovations for minimally invasive oncology.
✅ Strategic Dialogues: Explore potential collaboration and joint initiatives to introduce new advanced technology and elevate oncology standards across Caribbean religion.
✅ Shared Goal: Bring new hope to cancer patients across the Caribbean region through substantive collaborations.

Join the Movement:
Let's redefine oncology care across emerging markets →
🔗 Full event recap: https://lnkd.in/gAgtqkqR

27/06/2025

🌟 Redefining Tumor Ablation: Hygea Shines at MYSIR Annual Scientific Meeting 2025!
We're proud to announce Hygea Medical's participation in the Malaysian Society of Interventional Radiology (MYSIR) Annual Scientific Meeting 2025 (June 18-21)!
🔹 Showcased Innovation: Introduced our groundbreaking Exceed™ Microwave Ablation technology to global experts, featuring live demos and deep-dive sessions.
🔹 The Future is Here: Hygea's "spherical" abaltion system – merging precision ablation with full digital intelligence – is elevating the standards of tumor therapy.
✅ Spherical ablation | ✅ Higher precision | ✅ Faster recovery
Grateful for the vibrant exchanges with interventional radiologists and partners worldwide. Together, we're advancing minimally invasive cancer care!
👉 Stay tuned as we continue pushing boundaries.
https://lnkd.in/gAgtqkqR

25/06/2025

🚀 Global Experts Unite at ISMIO 2025: Advancing Tumor Ablation Innovations!
🎉 Thrilled to highlight the success of ISMIO 2025 International Conference in Suzhou (June 7), where leading oncologists from China, Russia, Turkey, Kazakhstan, Pakistan, and beyond convened to shape the future of minimally invasive cancer therapy! 🔬
Key Focus Areas:
💊 Cutting-edge applications of cryoablation & microwave ablation in solid tumors.
🧬 Breakthroughs in Co-Ablation technology for precision oncology.
Strategies to enhance global collaboration in interventional and multidisciplinary cancer care.
🌎 A monumental step toward transforming patient outcomes through innovation and cross-border knowledge exchange! 🌍✨

👉 P.S. Missed the session? Connect to explore key insights!
https://www.hygeamedtech.com/ismio-2025-hygea-symposium-unites-nations-on-cutting-edge-tumor-ablation-techniques.html

03/06/2025

🔥 Join Us at ISMIO 2025!
We're thrilled to announce Hygea Medical's spotlight session at ISMIO 2025!

📅 Date: 7 June 2025
⏰ Time: 16:00-18:00 (CST)
📍 Venue: Meeting Room F1, Worldhotel Grand Dushulake, Suzhou

Symposium Focus:
✨ “Tumor Ablation & Cryo-Thermal Techniques”
Hear pioneering insights from global experts representing:
🇨🇳 China | 🇷🇺 Russia | 🇹🇷 Turkey | 🇰🇿 Kazakhstan | 🇵🇰 Pakistan

Key Discussion Topics:
• HCC & pancreatic CA ablation advances
• Prostate cancer minimally invasive solutions
• Breakthroughs in Hygea's Co-ablation system
• Novel approaches to cancer pain management

Why Attend?
✅ Explore cutting-edge clinical evidence
✅ Network with KOLs in minimally interventional oncology
✅ Witness live demos of new-gen ablation systems


显示译文

03/06/2025

🚀 Hygea Medical Debuts in North America at WHX Miami! 🚀

Mark your calendars for June 11-13 as we unveil our groundbreaking Hygea Co-ablation Technology at WHX Miami (formerly FIME) – our first-ever American showcase!

🗓️ Date: June 11-13, 2025

📍 Location: Miami Beach Convention Center (MBCC), in Miami Beach, Florida, USA.

Visit us at Booth to explore how our System provide the advanced ablation solutions for solid tumors! 🌟
✅ Higher precision | ✅ Faster recovery | ✅ Enhanced patient
outcomes
https://lnkd.in/gAgtqkqR

28/05/2025

🌟 Honored to Collaborate for Global Health Impact! 🌟

We are profoundly honored to receive a gracious invitation from H.E. Ambassador Choo Anyin of Embassy of The Cooperative Republic of Guyana to Mr.Luo Fuliang, President of Hygea Medical, for the "Guyana CELEBRATES 59 YEARS OF INDEPENDENCE" on May 23rd. This momentous occasion marks a pivotal step in fostering Sino-Guyanese collaboration in healthcare advancement.

❄️ At Hygea Medical, with a focus on the minimally invasive oncology, we are committed to developing trustworthy solutions that enhance the quality of medical care, making a positive impact on the lives of cancer patients worldwide.

🌍 A Shared Vision for the Future 🌍
Partnering with visionary leaders like Ambassador Choo, we aim to deliver innovative medical solutions that to bridge healthcare gaps and elevate lives and well-being for patients in Guyana and the broader Caribbean region！